Electroporation-immunotherapy probe system for solid tumors
This technology combines a physical tumor-destruction technique called irreversible electroporation (IRE) with immunotherapy to treat cancer. IRE uses precisely tuned electrical pulses delivered through a probe inserted into a tumor to kill cancer cells, and the dying cells release signals that activate the body's immune system. By pairing this with immunotherapy agents, the treatment trains the immune system to recognize and attack cancer cells elsewhere in the body, including distant metastases. The result is a localized treatment that triggers a systemic anti-tumor immune response.
What you could build
A clinical protocol and probe system combining IRE ablation hardware with co-administered immunotherapy agents, sold to interventional oncology centers and hospital cancer programs seeking abscopal-effect treatments for solid tumors with metastases.
Who in Virginia should care
Virginia hospital systems and academic medical centers with interventional radiology or oncology programs, such as UVA Health or Inova, would be natural early adopters or clinical partners.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Rafael V. Davalos, John H. Rossmeisl, Paulo A. Garcia
- Granted
- August 29, 2023
- Status
- Granted patent
- Patent number
- 11737810
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.